CANCER BUZZ speaks with Srdan Verstovsek, MD, PhD, about when to begin therapeutic care for myeloproliferative neoplasms (MPNs) and the urgency of treatment.
As myeloproliferative neoplasms (MPNs) are a group of progressive blood cancers that can develop quickly into more serious hematological diseases, hear what community practices need to know about treating these patients quickly and the impact that timeliness of care can have on patient outcomes. In this episode, CANCER BUZZ speaks with Srdan Verstovsek, MD, PhD, United Energy Resources Inc. professor of Medicine and hematologist oncologist at MD Anderson Cancer Center, University of Texas, about when to begin therapeutic care for MPNs and the urgency of treatment.
“We learned from experience over the last ten to twenty years that early intervention—when things are not too bad—will actually help us achieve the goals of therapy. We will have a chance to significantly decrease the size of the spleen or improve the quality of life if we do not wait for patient to be terribly sick. So, early intervention in terms of identifying the problem, objectivizing it, [and recognizing] that the symptoms are there, [indicate that we] should start the therapy now—why wait?” – Srdan Verstovsek, MD, PhD
This is the second video podcast in a four-episode series on myeloproliferative neoplasms in connection with the education program “Advancing Care for Patients with Myeloproliferative Neoplasms (MPNs).” This episode is supported by Incyte.
Guest
Srdan Verstovsek, MD, PhD
Professor of Medicine, Department of Leukemia, Division of Cancer Medicine
Hematologist Oncologist
MD Anderson Cancer Center, University of Texas
Houston, TX
Resources:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
